24. Style, Substance, and Solutions: Generating Evidence in Infectious Diseases Therapeutics
Thursday, October 8, 2015: 8:30 AM-10:00 AM
Room: 33--ABC

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • identify new statistical approaches used in infectious diseases research
  • recognize clinical trials design strategies in infection control and antibiotic stewardship
  • discuss practical and pragmatic clinical trials design strategies in resource poor environments

Target Audience: Scientists, Researchers, Microbiologists, Members-in-training, Investigators, Infectious diseases physicians, Infectious diseases pediatricians, Infection preventionists, Hospital epidemiologists, Fellows, Epidemiologists, Clinicians, Academicians

Tracks: Trainee, Pediatric ID, Investigative ID, HIV-STD-TB, Global ID, Epidemiology and Infection Control, Adult ID

Moderator:  Vance G. Fowler Jr., MD, Duke University Medical Center

9:00 AM
Clinical Trials in Infection Control and Stewardship
Anthony D. Harris, MD, MPH, FIDSA, FSHEA

9:30 AM

CME Credits: Maximum of 1.5 hours of AMA PRA Category 1 CreditTM

ACPE Credits: ACPE 1.50 knowledge-based contact hours (0.150 CEU) of pharmacy CE

ACPE Number: 0221-9999-15-149-L04-P


V. G. Fowler Jr., Pfizer, Novartis, Galderma, Novadigm, Durata, Debiopharm, Genentech, Achaogen, Affinium, Medicines Co., Cerexa, Tetraphase, Trius, MedImmune, Bayer, Theravance, Cubist, Basilea: Consultant , Consulting fee
NIH, MedImmune, Forest/Cerexa, Pfizer, Merck, Advanced Liquid Logics, Theravance, Novartis, Cubist: Grant Investigator , Grant recipient , Research grant , Research support and Salary
Duke University Medical Center: Employee , Salary
NCGR/ Duke University: Patent pending , Intellectual property
UpToDate: Royalties , Licensing agreement or royalty
Merck: Board Member , Chair, V710 S. aureus vaccine Scientific Steering Committee
Green Cross, Cubist, Cerexa, Durata, Theravance: payment for educational lecture , Speaker honorarium

See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.